1. Home
  2. XRTX vs POAS Comparison

XRTX vs POAS Comparison

Compare XRTX & POAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XORTX Therapeutics Inc.

XRTX

XORTX Therapeutics Inc.

HOLD

Current Price

$2.19

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Logo Phaos Technology Holdings (Cayman) Limited Class A Ordinary Shares

POAS

Phaos Technology Holdings (Cayman) Limited Class A Ordinary Shares

HOLD

Current Price

$0.19

Market Cap

4.6M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
XRTX
POAS
Founded
2011
2017
Country
Canada
Singapore
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
4.3M
4.6M
IPO Year
2018
2024

Fundamental Metrics

Financial Performance
Metric
XRTX
POAS
Price
$2.19
$0.19
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
13.3K
236.3K
Earning Date
05-15-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.35
$0.17
52 Week High
$3.60
$7.40

Technical Indicators

Market Signals
Indicator
XRTX
POAS
Relative Strength Index (RSI) 57.19 33.11
Support Level $2.00 $0.19
Resistance Level $2.24 $0.39
Average True Range (ATR) 0.11 0.03
MACD 0.02 0.02
Stochastic Oscillator 81.25 24.90

Price Performance

Historical Comparison
XRTX
POAS

About XRTX XORTX Therapeutics Inc.

XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.

About POAS Phaos Technology Holdings (Cayman) Limited Class A Ordinary Shares

Phaos Technology Holdings Cayman Ltd is an investment holding company incorporated in the Cayman Islands. Through its subsidiaries, the Company engages in the research, development, manufacturing, and commercialization of advanced optical technologies and products. Leveraging its patented microsphere technology, Phaos enhances the magnification of traditional optical microscopes, enabling visualization beyond the 200nm optical limit at a commercially viable working distance. The Company offers advanced microscopy equipment and parts, along with AI-powered software solutions that complement its hardware to deliver fully integrated microscopy systems. Its technologies serve diverse sectors, including manufacturing, biomedical, and research.

Share on Social Networks: